Table 2 Correlation between SLFN5 expression and pathological parameters in ovarian carcinoma patients
From: SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
Factors | Cases | Low SLFN5 n(%) | High SLFN5 n(%) | P-value |
|---|---|---|---|---|
Age at diagnosis(y) | NS | |||
 ≦52 | 13 | 7 (53.8%) | 6 (46.2%) | |
  > 52 | 14 | 5 (35.7%) | 9 (64.3%) | |
FIGO stage |  < 0.05 | |||
 I and II | 9 | 2 (22.2%) | 7 (78%) | |
 III and IV | 18 | 5 (27.8%) | 13 (72.2%) | |
Lymph node metastasis | NS | |||
 pN0/pNX | 11 | 6 (54.5%) | 5 (45.5%) | |
 pN1 | 16 | 6 (37.5%) | 10 (62.5%) | |
Distant Metastasis |  < 0.05 | |||
 pM0/pMX | 9 | 3 (33.3%) | 6 (66.7%) | |
 pM1 | 18 | 4 (22.2%) | 14 (77.8%) | |
Histology | NS | |||
 Serous | 14 | 5 (45.45%) | 9 (56.25%) | |
 Clear cell | 4 | 1 (25%) | 3 (75%) | |
 Endometrioid | 7 | 2 (28.56%) | 5 (71.5%) | |
 Mucinous | 2 | 1 (50%) | 1 (50%) |